指南与共识流行病学与生物统计真实世界研究与卫生经济

析因随机对照试验的经济学评价:挑战、方法与推荐

Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.
指南 / 共识 · Stat Med · 2017-05-03

本文探讨析因随机对照试验中开展经济学评价的挑战,包括成本与质量调整生命年(QALY)的交互作用更常见、经济学终点的转换与回归分析难题,以及需同时考虑两个因素以评估最佳价值组合。文章通过假设示例演示分析方法对结果与结论的影响,并提出针对析因试验经济学评价的设计、分析与报告推荐。

要点

  • 忽略交互作用会引入偏倚,可能导致采用未最佳利用医疗资源的治疗。
  • 考虑所有交互作用可避免偏倚,但会降低统计效能。
  • 提出「忽略交互作用的机会成本」作为衡量未考虑所有交互作用所致偏倚的指标。

核心结论

  • 忽略交互作用会引入偏倚,可能导致采用未最佳利用医疗资源的治疗;考虑所有交互作用可避免偏倚但降低统计效能;作者提出针对析因试验经济学评价的设计、分析与报告推荐,并考虑增加的分析成本。

研究设计与样本

  • 本文为方法学文章,结合假设性示例说明析因随机对照试验中经济学评价的挑战与分析方法,并提出推荐。

主要发现

  • 析因试验中成本与质量调整生命年(QALY)的交互作用可能比临床终点更常见;经济学终点在转换与回归分析方面存在挑战;需同时考虑两个因素以评估哪种治疗组合最具成本效益。
  • 忽略交互作用会引入偏倚,考虑所有交互作用可避免偏倚但降低统计效能;文章提出「忽略交互作用的机会成本」作为偏倚度量。

关键数值与推荐

  • 原文未报告具体数值标准或推荐等级。

临床怎么用

  • 作者建议健康经济学家、统计学家和试验研究者在对析因试验进行经济学评价时,应同时考虑两个因素以评估最佳价值组合,并权衡考虑交互作用带来的分析成本增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing numbers of economic evaluations are conducted alongside randomised controlled trials. Such studies include factorial trials, which randomise patients to different levels of two or more factors and can therefore evaluate the effect of multiple treatments alone and in combination. Factorial trials can provide increased statistical power or assess interactions between treatments, but raise additional challenges for trial-based economic evaluations: interactions may occur more commonly for costs and quality-adjusted life-years (QALYs) than for clinical endpoints; economic endpoints raise challenges for transformation and regression analysis; and both factors must be considered simultaneously to assess which treatment combination represents best value for money. This article aims to examine issues associated with factorial trials that include assessment of costs and/or cost-effectiveness, describe the methods that can be used to analyse such studies and make recommendations for health economists, statisticians and trialists. A hypothetical worked example is used to illustrate the challenges and demonstrate ways in which economic evaluations of factorial trials may be conducted, and how these methods affect the results and conclusions. Ignoring interactions introduces bias that could result in adopting a treatment that does not make best use of healthcare resources, while considering all interactions avoids bias but reduces statistical power. We also introduce the concept of the opportunity cost of ignoring interactions as a measure of the bias introduced by not taking account of all interactions. We conclude by offering recommendations for planning, analysing and reporting economic evaluations based on factorial trials, taking increased analysis costs into account. © 2017 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Dakin H, Gray A. Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations. Stat Med. 2017. PMID: 28470760. doi:10.1002/sim.7322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。